Association between YKL-40 and adult primary astrocytoma

Cancer

Volumn 116, Issue 11, 2010, Pages 2688-2697

  Zhang, Wei ^a,b   Kawanishi, Masahiko ^b   Miyake, Keisuke ^b   Kagawa, Masahiro ^b   Kawai, Nobuyuki ^b   Murao, Koji ^c   Nishiyama, Akira ^b   Fei, Zhou ^a   Zhang, Xiang ^a   Tamiya, Takashi ^b  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b KAGAWA UNIVERSITY   (Japan)

^c KAGAWA UNIVERSITY   (Japan)

Author keywords

Astrocytoma; Mitogen activated protein kinase; Proliferation; Small interfering RNA; YKL 40

Indexed keywords

4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; GLYCOPROTEIN; GLYCOPROTEIN YKL 40; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE 9; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN KINASE B; SMALL INTERFERING RNA; STRESS ACTIVATED PROTEIN KINASE 1; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASTROCYTOMA; ASTROCYTOMA CELL; CANCER GRADING; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH;

ADULT; ASTROCYTOMA; BRAIN NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GLIOMA; GLYCOPROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; LECTINS; MALE; MAP KINASE SIGNALING SYSTEM; MIDDLE AGED; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 77952854217     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.25084     Document Type: Article

References (28)

1. Mizumatsu S, Tamiya T, Ono Y, et al. Expression of cell-cycle regulator p27Kip1 is correlated with survival of patients with astrocytoma. Clin Cancer Res. 1999;5:551-557. (Pubitemid 29131964)
2. Tamiya T, Mizumatsu S, Ono Y, et al. High cyclin E/low p27Kip1 expression is associated with poor prognosis in astrocytomas. Acta Neuropathol (Berl). 2001;101:334-340.
3. Jensen BV, Johansen JS, Price PA. High levels of serum HER-2/neu and YKL-40 independently reflect aggressiveness of metastatic breast cancer. Clin Cancer Res. 2003;9:4423-4434. (Pubitemid 37248400)
4. Johansen JS, Drivsholm L, Price PA, Christensen IJ. High serum YKL-40 level in patients with small cell lung cancer is related to early death. Lung Cancer. 2004;46:333-340. (Pubitemid 39487308)
5. Brasso K, Christensen IJ, Johansen JS, et al. Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate. 2006;66:503-513.
6. Hogdall EV, Johansen JS, Kjaer SK, et al. High plasma YKL-40 level in patients with ovarian cancer stage III is related to shorter survival. Oncol Rep. 2003;10:1535-1538.
7. Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer. 2006;106:1130-1139; erratum in Cancer. 2006;107:2315.
8. Schmidt H, Johansen JS, Sjoegren P, et al. Serum YKL-40 predicts relapse-free and overall survival in patients with American Joint Committee on Cancer stage I and II melanoma. J Clin Oncol. 2006;24:798-804. (Pubitemid 46622047)
9. Tanwar MK, Gilbert MR, Holland EC. Gene expression microarray analysis reveals YKL-40 to be a potential serum marker for malignant character in human glioma. Cancer Res. 2002;62:4364-4368.
10. Hormigo A, Gu B, Karimi S, et al. YKL-40 and matrix metalloproteinase-9 as potential serum biomarkers for patients with high-grade gliomas. Clin Cancer Res. 2006;12:5698-5704. (Pubitemid 44629598)
11. Saidi A, Javerzat S, Bellahcene A, et al. Experimental anti-angiogenesis causes upregulation of genes associated with poor survival in glioblastoma. Int J Cancer. 2008;122:2187-2198. (Pubitemid 351542321)
12. Shostak K, Labunskyy V, Dmitrenko V, et al. HC gp-39 gene is upregulated in glioblastomas. Cancer Lett. 2003;198:203-210.
13. Pelloski CE, Mahajan A, Maor M, et al. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. Clin Cancer Res. 2005;11:3326-3334. (Pubitemid 40627883)
14. Nigro JM, Misra A, Zhang L, et al. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. Cancer Res. 2005;65:1678-1686. (Pubitemid 40478592)
15. Junker N, Johansen JS, Hansen LT, Lund EL, Kristjansen PE. Regulation of YKL-40 expression during genotoxic or microenvironmental stress in human glioblastoma cells. Cancer Sci. 2005;96:183-190. (Pubitemid 40575920)
16. Zhen HN, Zhang X, Hu PZ, et al. Survivin expression and its relation with proliferation, apoptosis, and angiogenesis in brain gliomas. Cancer. 2005;104:2775-2783. (Pubitemid 41798288)
17. Friedrich M, Villena-Heinsen C, Reitnauer K, Schmidt W, Tilgen W, Reichrath J. Malignancies of the uterine corpus and immunoreactivity score of the DNA "mismatch-repair" enzyme human Mut-S-homologon-2. J Histochem Cytochem. 1999;47:113-118.
18. Kurozumi K, Tamiya T, Ono Y, et al. Apoptosis induction with 5-fluorocytosine/cytosine deaminase gene therapy for human malignant glioma cells mediated by adenovirus. J Neurooncol. 2004;66:117-127. (Pubitemid 38258366)
19. Zhang W, Fei Z, Zhen HN, Zhang JN, Zhang X. Resveratrol inhibits cell growth and induces apoptosis of rat C6 glioma cells. J Neuro-Oncol. 2007;81:231-240. (Pubitemid 46165325)
20. Nutt CL, Betensky RA, Brower MA, Batchelor TT, Louis DN, Stemmer-Rachamimov AO. YKL-40 is a differential diagnostic marker for histologic subtypes of high-grade gliomas. Clin Cancer Res. 2005;11:2258-2264.
21. Rousseau A, Nutt CL, Betensky RA, et al. Expression of oligodendroglial and astrocytic lineage markers in diffuse gliomas: use of YKL-40, ApoE, ASCL1, and NKX2-2. J Neuropathol Exp Neurol. 2006;65:1149-1156. (Pubitemid 44888831)
22. Recklies AD, White C, Ling H. The chitinase 3-like protein human cartilage glycoprotein 39 (HC-gp39) stimulates proliferation of human connective-tissue cells and activates both extracellular signal-regulated kinase- and protein kinase B-mediated signalling pathways. Biochem J. 2002;365:119-126. (Pubitemid 34756146)
23. Ling H, Recklies AD. The chitinase 3-like protein human cartilage glycoprotein 39 inhibits cellular responses to the inflammatory cytokines interleukin-1 and tumor necrosis factor-alpha. Biochem J. 2004;380:651-659. (Pubitemid 38850506)
24. Mawrin C, Diete S, Treuheit T, et al. Prognostic relevance of MAPK expression in glioblastoma multiforme. Int J Oncol. 2003;23:641-648.
25. Pelloski CE, Lin E, Zhang L, et al. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. Clin Cancer Res. 2006;12:3935-3941.
26. Thornton TM, Rincon M. Non-classical p38 map kinase functions: cell cycle checkpoints and survival. Int J Biol Sci. 2009;5:44-51.
27. Kennedy NJ, Sluss HK, Jones SN, Bar-Sagi D, Flavell RA, Davis RJ. Suppression of Ras-stimulated transformation by the JNK signal transduction pathway. Genes Dev. 2003;17:629-637. (Pubitemid 36307547)
28. Recklies AD, Ling H, White C, Bernier SM. Inflammatory cytokines induce production of CHI3L1 by articular chondrocytes. J Biol Chem. 2005;280:41213-41221. (Pubitemid 41832176)